Drug Trial Radar · NCT07253428
Emergence Agitation
Last checked: Nov 20, 2026Latest source record: Nov 28, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
486
Planned (sponsor's estimate)
Start
Oct 30, 2025
Primary completion
Dec 31, 2025
Study completion Jan 31, 2026
Sponsor
- Lead sponsor
- Ain Shams UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Nov 28, 2025
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 60 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The impact of sugammadex on agitation upon emergence following adult nasal surgeries is an issue which needs to be studied that links anesthetic management with postoperative recovery.
Conditions
- Emergence Agitation
- Nasal Surgery
Interventions
Neostigmine + AtropineDrug
Neostigmine group will receive the neostigmine as a reversal of the muscle relaxant; rocuronium
SugamadexDrug
Sugamadex group will receive sugamadex as a reversal agent of the muscle relaxant; rocuronium Neostigmine group will receive the neostigmine as a reversal of the muscle relaxant; rocuronium. Both interventions will be used to compare the effect of adequate muscle relaxation upon the emergence agitation.
Primary outcomes
What the sponsor says the trial is designed to measure.
- the incidence of emergence agitation following adult nasal surgeries in patients receiving sugammadex versus a traditional neuromuscular blocking agent reversal method.Time frame: perioperative
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Rabah Alharbi
Ha'il, Saudi Arabia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.